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Introduction
A number of human myeloid leukemia cell lines arrest-
ed at different stages of differentiation have been
established over the years and they provide good mod-
els for studies of acute myeloid leukemia (AML). Fur-
ther differentiation of these lines can be induced by
various agents, for example, all-trans retinoic acid
(ATRA) and phorbol 12-myristate 13-acetate (PMA)
[1-5]. 
ATRA, an isoform of retinoic acid (the active
metabolite of vitamin A) seems to play an important
role in the control of hematopoiesis and regulates cell
growth and differentiation [6-8]. PMA is a stable ana-
logue of 2,3-diacyloglicerol that activates isoform of
protein kinase C (PKC) [9,10]. In vitro studies have
shown that human leukemia cell lines: HL60
(myeloblastic) and NB4 (promyelocytic) can be
induced to enter diferentiation along the neutrophil lin-
eage upon stimulation with ATRA or along the mono-
cyte lineage after PMA treatment, resulting in mor-
phological and functional changes accompanied by a
loss of proliferative capacity. Moreover, differentiation
therapy with ATRA has been proved to be very effec-
tive and has now become an established method of
treatment in acute promyelocytic leukemia (APL) [11-
15].
It is not clear whether differentiation agents have an
effect on leukemia cell sensitivity to chemotherapeutic
drugs. Common anticancer drugs can stop cell prolif-
eration and/or induce cell death: apoptosis or necrosis,
but a major limitation of such conventional therapy is
drug resistance of leukemic cells. On the one hand, dif-
ferentiated cells which are arrested in G0 phase may be
less sensitive to anticancer agents because cytotoxic
effect on tumor cells is stronger when cells are in S
phase of the cell cycle. On the other hand, induction of
differentiation may provide changes in pro- and anti-
apoptotic gene expression, facilitating apoptosis in
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leukemic cells: ATRA downregulates bcl-2 expression
and increases AML sensitivity to cytosine arabinoside
(Ara-C) induced apoptosis in vitro [13,16].
The aim of this study was to examine the potential
cytostatic and cytotoxic effect of drugs conventionaly
used in AML treatment (Ara-C, daunorubicin, mitox-
antrone and etoposide) on HL60 and NB4 cell lines,
following incubation with ATRA or PMA.
Materials and methods
Drugs. ATRA (Sigma) and PMA (Sigma) were dissolved in
DMSO to get stock solutions of 1 mM and 1.6 mM, respectively;
these were stored at -20°C until required. The final concentration
of DMSO in cultures did not exceed 0.1% v/v. All cytotoxic drugs
(Ara-C, daunorubicin, mitoxantrone and etoposide) used in this
study were purchased from Sigma. Concentrated stock solutions in
distilled water were stored at -20°C.
Cell culture. Human AML cell lines HL60 (ATTC CCL 240) and
NB4 (DSM ACC 207) were cultured in RPMI 1640 (Gibco, USA)
supplemented with 10% (v/v) FBS (Gibco, USA), 2 mM L-gluta-
mine (Gibco, USA) and 50 μg/ml gentamycine. Cells were grown
at 37°C in a humidified 5% CO2 atmosphere and were routinely
subcultured every 2-3 days.
For the experiments, HL60 and NB4 cells were seeded at 0.1 ×
106/ml in 25-cm2 culture flasks (Costar) in culture medium and
supplemented with 1 μM ATRA or 1.6 nM PMA. Cells were har-
vested after 24, 48 and 72 hours and used for assays to evaluate cell
differentiation.
Cell differentiation assessment
Cell proliferation. The total number of cells was determined by
manual counting in Bürker chamber.
Morphology. Smears of control and ATRA/PMA-treated cells
were stained with May-Grünwald solution (Merck, Germany) for 2
minutes, rinsed with distilled water and stained with Giemsa (0.4%
solution in methanol; Sigma, Germany) for 10 minutes. Slides
were rinsed thoroughly with distilled water and air dried. Cell mor-
phology was studied by light microscopy under immersion.
Nitroblue tetrazolium (NBT) reduction assay. In order to evaluate
the differentiation induction in NB4 and HL60 cells, NBT assay, a
reliable marker for differentiation of myeloid leukemia cells, was
carried out on ATRA- and PMA-treated cells. Cells (0.5 × 106)
were harvested at the indicated times, resuspended in 2 ml RPMI
1640 medium containing 0.1% nitroblue tetrazolium salt (NBT;
Sigma) and 100 ng/ml PMA, and incubated for 15 minutes at 37°C
in the dark. The percentage of cells containing reduced dark blue
formazan deposits was determined in duplicate, under light micro-
scope, by examining 200 cells.
Expression of CD11b and CD14 myeloid differentiation anti-
gens. CD11b characterizes both granulocytic and monocytic dif-
ferentiation; CD14 is specific to monocytic differentiation. To
measure their expression, cells were suspended in culture medium
at 0.5 × 106/0.5 ml and plated onto slides coated with 0.1% poly-
L-lysine (Sigma, USA). Cells were allowed to attach for 1.5 h at
37°C in humidified atmosphere with 5% CO2, washed once with
PBS and fixed with cold (-20°C) methanol:acetone (1:1) for 10 min-
utes at  4°C. Following triple rinse with PBS, cells were incubated at
room temperature for 30 minutes in 100 μl of primary antibody dilu-
tor (PAD) comprising 10% normal goat serum, 0.1% bovine serum
albumin, 0.05% thimerosal and 0.01% NaN3 (all from Sigma). The
primary mouse monoclonal antibodies: anti-CD11b (Novocastra
Ltd., Newcastle upon Tyne, UK, NCL-CD11b; diluted 1:100) and
anti-CD14 (Novocastra Ltd., Newcastle upon Tyne, UK, NCL-
CD14-223; diluted 1:100) were added to the cells (after ATRA and
PMA incubations and after PMA incubation, respectively) and
incubated overnight at room temperature. The next day, the cells
were washed once with PBS, and incubated with the secondary
antibody, a Cy3-coniugated goat anti-mouse IgG (Jackson IR, West
Grove, PA, USA, 115-165-146; diluted 1:400) for 60 minutes in
the dark. Cells were rinsed with PBS again and slides were mount-
ed in glycerin/PBS (2:1). Negative control was performed by
replacing the primary or secondary antibodies with PAD.
Slides were examined in the fluorescence microscope (Olym-
pus BX100) equipped with U-MNG filter set. For each set of con-
ditions, duplicate experiments were performed, and at least 100
cells per slide were counted to determine the percentage of
immunopositive cells.
Drug treatment of cell lines after differentiation. Cells incubat-
ed with ATRA or PMA were washed and treated with chemothera-
peutic drugs: cytosine arabinoside (48 μM), daunorubicin (0.16
μM), mitoxantrone (0.8 μM) or etoposide (16 μM) for 24 hours.
72-h cultures with PMA were excluded from this part of experi-
ment because of decreased cell number and increased apoptosis.
Drug concentrations chosen reflected the doses which resulted in a
50% decrease in cell survival (LD50). These concentrations were
based on results of our previous in vitro studies (data not shown).
Control cultures in drug-free medium were carried out in parallel.
Assessment of drug effect. The cell survival and cytotoxic effect
was determined using Alamar Blue reduction assay. After incuba-
tion with ATRA or PMA, washed cells were resuspended at 2
×105/ml in culture medium with Alamar Blue (0.2%) and then
placed into 96-well plates in the volume of 100 μl/well. Cells were
incubated at 37°C in humidified atmosphere with 5% CO2 for 2
hours in the dark and then the intensity of fluorescence emitted
with the reduction of Alamar Blue was measured with Microplate
Fluorescence Reader FL600 (Bio-Tek Instruments, Inc., Vermont,
USA) (excitation wave: 530-560 nm, emission wave: 590 nm) to
evaluate fluorescence level before drug additon. Next, drugs were
added to the wells. After 24 h cells were washed by plate centrifu-
gation, resuspended in fresh culture medium containing 0.2% Ala-
mar Blue and assessed again as described above. The proliferation
and survival rates were calculated according to the formulas: 
Cell growth index (% proliferation) = Fluorescence signal intensi-
ty after incubation with drug / Fluorescence signal intensity before
incubation with drug × 100%; 
Survival index (% viability) = Fluorescence signal intensity after
incubation with drug / Fluorescence signal intensity for untreated
control x 100%.
Identification and quantification of apoptotic cells with
Hoechst 33342. Nuclear morphology of control and treated cells
was studied by fluorescence microscopy after staining cell nuclei
with Hoechst 33342 (Sigma); apoptotic cells were characterized by
condensation of chromatin and/or nuclear fragmentation. The
smears, prepared on glass slides, were washed twice in PBS
(pH=7.4), fixed in formaldehyde (4% solution in PBS) for 15 min-
utes at room temperature and incubated with Hoechst 33342 
(5 μg/ml in distilled water) for 10 minutes at room temperature.
They were then washed 5 times in PBS, mounted in glycerin/PBS
solution (1:2) and coverslipped. Cells (at least 100 per slide) were
examined under a fluorescence microscope (Olympus BX50) by
using the MNU2 filter.
Statistical analysis. Data are expressed as mean ± standard error
of 5 experiments. Results were analysed using one-way analysis of
variance. P-values <0.05 were regarded as significant. Statistical
analysis was performed using Statgraphics 2.1 for Windows
(Manugistic, USA).
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Results
ATRA and PMA inhibit proliferation of HL60
and NB4 cell lines
The anti-proliferative effect of ATRA and PMA was
studied by measuring the total number of cells in each
culture. As shown in Fig. 1, ATRA and PMA signifi-
cantly (p<0.001 and p<0.005, respectively) inhibited
proliferation of both HL60 and NB4 cells after 48- and
72 hours, in comparison with untreated control. This
effect was strongest in PMA-treated cells.
Morphological changes
Incubation with ATRA or PMA resulted in morpholog-
ical changes of cells revealed by May-Grünwald-
Giemsa staining. As shown in Fig. 2, morphological
features of granulocytic differentiation, such as seg-
mented nuclei and condensed chromatin were clearly
evident in ATRA-treated HL60 and NB4 cell lines.
PMA-treated leukemia cells displayed features typi-
cal of mature monocytes and macrophages and not found
in control cells: decreased nucleocytoplasmic ratio, chro-
matin condensation, round or oval peripherally located
nucleus, irregular cytoplasmic contours and greyish
cytoplasm. Cell cultures with PMA analysed after 72 h
displayed a moderate number of apoptotic cells.
In the absence of ATRA or PMA, no sign of granu-
locytic or monocytic maturation was observed in
either HL60 or NB4 cells.
NBT assay
The ability of cells to reduce NBT was observed 24h
after ATRA or PMA treatment and increased significant-
ly after 48 and 72 h. HL60 cells were more sensitive to
PMA stimulation: the number of NBT-positive cells was
significantly higher after treatment with PMA than with
ATRA. Moreover, the effect of ATRA was considerably
lower in these cells than in NB4 cells.
The NB4 cells showed similarly high NBT reduction
after ATRA- and PMA-treatment. About 10% of untreat-
ed HL60 and NB4 cells were NBT-positive (Fig. 3).
Expression of surface antigens
About 3% of unstimulated cells expressed CD11b and
CD14 cell surface antigens. The population of CD11b-
and CD14-positive cells increased by almost 20-40%
after 24 h incubation with differentiating agents:
ATRA or PMA. For both cell lines, the percentage of
CD11b-possitive cells was the highest after ATRA
treatment. The percentage of cells expressing CD14
(only after PMA stimulation) was higher in HL60 cells
than in NB4 cells; the differences were statistically
significant after 48- and 72 h (p<0.05) (Fig. 4). 
Drug sensitivity of cells after differentiation
After ATRA or PMA treatment, both cell lines showed
similar behavior in response to drugs.
ATRA-induced differentiation. Preincubation with
ATRA increased sensitivity of cells towards Ara-C or
mitoxantrone compared with unstimulated cells, as
reflected by decreased proliferation and survival rates
(cytostatic and cytotoxic effects) (p<0.05). An oppo-
site effect was observed for etoposide (p<0.05). Pre-
treatment with ATRA did not change the cell sensitiv-
ity to daunorubicin. These results were confirmed by
apoptosis rate: preincubation with ATRA significantly
increased apoptosis in Ara-C treated cells and reduced
apoptosis induced by etoposide. ATRA however, sta-
tistically decreased apoptosis rate after daunorubicin
treatment and did not significantly influence mitox-
antrone-induced apoptosis. Both HL60 and NB4 cells
stimulated to differentiation by ATRA showed similar
sensitivity to all drugs tested. The observed effects
were not dependent on the duration of ATRA pretreat-
ment (Fig. 5 A, C, E).
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Fig. 1. Growth inhibition of (A) HL60 and (B) NB4 cell lines after
ATRA (10-6 M) or PMA (1.6 nM) treatment. Data are means ± SD
of 5 independent experiments.
PMA-induced differentiation. The differentiation
after PMA treatment resulted in the decreased sensitiv-
ity of both HL60 and NB4 cells to all drugs tested. The
proliferation and survival rates were higher and the
apoptosis rate was markedly lower in PMA- prestimu-
lated cells than in unstimulated control (Fig. 5 B, D,
F). This effect was similar for all drugs and did not
depend on the duration of PMA pretreatment.
Discussion
Under experimental conditions of this study, ATRA
and PMA induced differentiation of HL60 and NB4
cells, manifested by inhibition of cell proliferation,
morphological changes, capacity of oxidative burst
production and expression of CD11b and CD14 differ-
entiation markers. All tested parameters indicating cell
differentiation were increased after ATRA- or PMA-
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Fig. 2. May-Grünwald-Giemsa
stained cytosmears of HL60 cells:
untreated (control) and treated
with ATRA or PMA. Arrows indi-
cate apoptotic cells (magnification
x400).
treatment, however, their dynamics was not identical.
According to NBT reduction assay results, HL60 cells
were much more capable to produce oxidative burst
after stimulation with PMA, whereas NB4 cells
showed similar response after ATRA and PMA.
CD11b and CD14 antigen expression was stronger
after ATRA treatment, while the cell proliferation was
strongly inhibited after PMA treatment. These diverse
effects suggest that different signalling pathways may
be involved in the regulation of the differentiation pro-
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Fig. 3. Induction of NBT-reducing ability of (A) HL60 and (B) NB4 cells. The percentage of cells (NBT-positive) containing reduced dark
blue formazan deposits was determined in duplicate, under light microscope, by examining 200 cells. Data are means ± SD of 5 inde-
pendent experiments.
Fig. 4. Effect of ATRA or PMA on the expression of the dif-
ferentiation markers: CD11b and CD14 in HL60 (A) and NB4
(B) cells. Duplicate experiments were performed, and at least
100 cells per slide were counted to determine the percentage of
cells showing red fluorescence. Data are means ± SD of 5
independent measurements. Light (C) and fluorescence (D)
microscopy images of the same field of ATRA-treated HL60
cells (72 h) (magnification ×200).
gram. Moreover, it has been reported that the differenti-
ation process in leukemia cells may be different than in
normal hematopoietic cells [17]. HL60 cell line has been
found to differentiate in response to ATRA into neu-
trophils which are not identical to normal mature cells
and do not always express the same antigens as mature
neutrophils. For example, ATRA does not induce on
HL60 cells the expression of CD16, CD66 and CD88
antigens, which are normally expressed on granulocytes
[18]. In addition, it has been noticed that neither fresh
APL cells nor promyelocytic cell lines express second-
ary granules after incubation with ATRA [19].
There is a growing number of publications docu-
menting that differentiation process of leukemia cells
may modulate their sensitivity to chemotherapeutic
drugs [20-24]. In our in vitro model we have shown
that ATRA increases sensitivity of HL60 and NB4 cells
to Ara-C and mitoxantrone. This is in agreement with
some data in the literature: previous studies have
shown that ATRA modulates the expression of pro-
and antiapoptotic proteins. The reduction of intercellu-
lar level of antiapoptotic Bcl-2 protein was found dur-
ing stimulation of differentiation in AML cell lines as
well as in normal hematopoietic progenitors
[11,25,26]. Moreover, other authors demonstrated that
NB4 cells incubated with ATRA overexpressed TRAIL
protein, a mediator of extrinsic apoptosis pathway
[27]. On the other hand, some standard chemothera-
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Fig. 5. Effect of Ara-C, daunorubicin, mitoxantrone and
etoposide on the proliferation (A, B), viability (C, D)
and apoptosis (E, F) of HL60 cells pretreated with
ATRA or PMA. Each value is the mean ± SD of 5
measurements. *significantly different from the corre-
sponding group of undifferentiated cells. G, H - repre-
sentative micrographs of Hoechst 33342-stained cells:
untreated control (G) 0.16 μM daunorubicin-treated
cells (H) (magnification ×200).
peutic drugs, such as Ara-C, when used at low concen-
trations can also induce differentiation of leukemia
cells [28,29]. Hence, the decreased cell survival
observed in our experiments after preicubation with
ATRA and subsequent treatment with anticancer
agents: Ara-C and mitoxantrone might be a summative
effect of two differentiation-inducing stimuli, ulti-
mately leading to apoptosis.
In contrast, the present study demonstrated that
HL60 and NB4 cells stimulated to differentiation
along the monocyte/macrophage pathway decreased
their sensitivity to all drugs tested. This is in accor-
dance with the results presenting by Sordet et al. [24]
who have shown that PMA inhibits etoposide-induced
apoptosis of HL60 and U937 cell lines, suggesting that
the failure of PMA-stimulated cells to enter apoptosis
might be the effect of protein kinase C (PKC) activa-
tion. However, this effect can also be independent of
PKC activity: it has been shown that PMA inhibits
sphingomyelinase activity and decreases ceramide
production preventing apoptosis [30] and that PMA-
treated cells are resistant to Fas-L-induced apoptotic
cell death [31]. Moreover, other studies have shown
that phorbol esters increase the level of antiapoptotic
proteins (Bcl-2, Bcl-XL, Mcl-1), especially in adher-
ent cells stimulated to differentiate [32-34].
It is interesting to note that differentiation inducers
may have an effect on cell cycle. It is well established
that the sensitivity of malignant cells to chemotherapeu-
tic drugs is highest when cells are in S- and G2/M phase.
Recent studies have shown that ATRA stimulation of
leukemia cells in vitro results in decreased fraction of
cells in the S and G2/M phase [22,35]. We have demon-
strated strongly decreased sensitivity to etoposide
induced by both ATRA and PMA. It might be due to
inhibition of topoisomerase II activity by etoposide - an
effect which is the strongest in S phase [36]. Another
possibility is increased efficiency of DNA repair
processes mediated by p21 protein in cells stimulated to
differentiation. The p21 protein is an inhibitor of cell
cycle regulated by p53. HL60 and NB4 cell lines lack
functional p53, hence induction of p21 protein during
differentiation may occur independently of p53, since
high p21 expression was observed in HL60 cells after
induction of differentiation [22,37]. 
In our studies, the sensitivity of ATRA-pretreated
cells towards daunorubicin did not change and was
decreased in cells preincubated with PMA. As reported
previously, decreased level of Bcl-2 protein in ATRA-
diferentiated HL60 and NB4 cells might be compensat-
ed by upregulation of other antiapoptotic proteins of Bcl-
2 family, e.g. Mcl-1 and Bfl-1/A1 [25,38-40]. Moreover,
it has been shown that doxorubicin (anthracycline drug
similar to daunorubicin) decreased apoptosis in ATRA-
treated APL cells and Bfl-1/A-1 may be responsible, at
least in part, for this effect [25]. Interestingly, daunoru-
bicin is thought to trigger both apoptotic and survival
pathways in the treated cells [41,42]. Anticancer agents
and differentiation inducers may then have different or
complementary effects on survival of leukemia cells.
The duration of treatment with ATRA or PMA did not
affect the level of cell sensitivity, suggesting that just the
initiation of differentiation process may be important for
the reaction of cells to chemotherapeutic drugs. It has
been reported that shorter treatment of HL60 and NB4
cells with ATRA (for 3-24 h) resulted in the upregulation
or downregulation of many genes involved in the initia-
tion of differentiation. For example, genes participating
in signal transduction pathways (retinoic acid receptor β)
were upregulated after 8 h [43,44]. 
We have to take into consideration, however, that
not only differentiation process but also the way of its
induction might be important for chemosensitivity of
cells. In our studies, we have observed different effects
of drugs upon treatments inducing granulocytic path-
way (ATRA) and monocytic pathway (PMA).
In conclusion, we have shown that ATRA- and
PMA-mediated differentiation of human myeloid
leukemia cell lines results in the changes of their drug
sensitivity. Our data may provide a contribution to a
strategy aimed at a rational combination of differenti-
ating agents and conventional anticancer drugs.
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